Effects of cannabidiol in the treatment of patients with Parkinson's disease: An exploratory double-blind trial

Journal of Psychopharmacology

Volumn 28, Issue 11, 2014, Pages 1088-1092

  Chagas, Marcos Hortes N ^a,b,c   Zuardi, Antonio W ^a,b   Tumas, Vitor ^a   Pena Pereira, Márcio Alexandre ^a   Sobreira, Emmanuelle T ^a   Bergamaschi, Mateus M ^a,b   Dos Santos, Antonio Carlos ^a,b   Teixeira, Antonio Lucio ^d   Hallak, Jaime E C ^a,b   Crippa, José Alexandre S ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b National Institute for Translational Medicine INCT TM CNPq   (Brazil)

^c Dr Paulo Prata FACISB   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

cannabidiol; cannabis; Parkinson's disease; treatment

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABIDIOL; PLACEBO; ASPARTIC ACID; BRAIN-DERIVED NEUROTROPHIC FACTOR, HUMAN; CREATINE; N-ACETYLASPARTATE; NEUROPROTECTIVE AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EXPLORATORY RESEARCH; FEMALE; HUMAN; MALE; NEUROPROTECTION; PARKINSON DISEASE; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITY OF LIFE; UNIFIED PARKINSON DISEASE RATING SCALE; WELLBEING; ANALOGS AND DERIVATIVES; BLOOD; METABOLISM; MIDDLE AGED; PUTAMEN; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPARTIC ACID; BRAIN-DERIVED NEUROTROPHIC FACTOR; CANNABIDIOL; CREATINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PROTON MAGNETIC RESONANCE SPECTROSCOPY; PUTAMEN; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84910076223     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881114550355     Document Type: Article

References (25)

1. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011 ; 36: 1219-1226
2. Chagas MH, Crippa JA, Zuardi AW, et al. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol. 2013 ; 27: 312-316
3. Chagas MH, Eckeli AL, Zuardi AW, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson's disease patients: A case series. J Clin Pharm Ther. 2014 ; 39: 564-566
4. Crippa JA, Zuardi AW, Martin-Santos R, et al. Cannabis and anxiety: A critical review of the evidence. Hum Psychopharmacol. 2009 ; 24: 515-523
5. Fahn S, Elton RL Recent Developments in Parkinson's Disease. Fahn S Marsden CD Calne DB, ed. Florahm Park, N.J.: Macmillan Health Care ; 1987 :
6. Fernandez-Ruiz J, Sagredo O, Pazos MR, et al. Cannabidiol for neurodegenerative disorders: Important new clinical applications for this phytocannabinoid?. Br J Clin Pharmacol. 2013 ; 75: 323-333
7. Fitzpatrick R, Jenkinson C, Peto V, et al. Desirable properties for instruments assessing quality of life: Evidence from the PDQ-39. J Neurol Neurosurg Psychiatry. 1997 ; 62: 104
8. Garcia-Arencibia M, Gonzalez S, De Lago E, et al. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent properties. Brain Res. 2007 ; 1134: 162-170
9. Hermann D, Sartorius A, Welzel H, et al. Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry. 2007 ; 61: 1281-1289
10. Iuvone T, Esposito G, De Filippis D, et al. Cannabidiol: A promising drug for neurodegenerative disorders?. CNS Neurosci Ther. 2009 ; 15: 65-75
11. Jenkinson C, Fitzpatrick R, Peto V, et al. The Parkinson's Disease Questionnaire (PDQ-39): Development and validation of a Parkinson's disease summary index score. Age Ageing. 1997 ; 26: 353-357
12. Jenkinson C, Peto V, Fitzpatrick R, et al. Self-reported functioning and well-being in patients with Parkinson's disease: Comparison of the short-form health survey (SF-36) and the Parkinson's Disease Questionnaire (PDQ-39). Age Ageing. 1995 ; 24: 505-509
13. Lastres-Becker I, Molina-Holgado F, Ramos JA, et al. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease. Neurobiol Dis. 2005 ; 19: 96-107
14. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987 ; 334: 1-100
15. Lotan I, Treves TA, Roditi Y, et al. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: An open-label observational study. Clin Neuropharmacol. 2014 ; 37: 41-44
16. Monti JM. Hypnoticlike effects of cannabidiol in the rat. Psychopharmacology (Berl). 1977 ; 55: 263-265
17. Saito VM, Wotjak CT, Moreira FA. [Pharmacological exploitation of the endocannabinoid system: New perspectives for the treatment of depression and anxiety disorders?]. Rev Bras Psiquiatr. 2010 ; 32: S7-14
18. Siderowf A, Mcdermott M, Kieburtz K, et al. Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: Results from a multicenter clinical trial. Mov Disord. 2002 ; 17: 758-763
19. Van Vliet SA, Vanwersch RA, Jongsma MJ, et al. Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model. Eur Neuropsychopharmacol. 2008 ; 18: 383-389
20. Venderova K, Ruzicka E, Vorisek V, et al. Survey on cannabis use in Parkinson's disease: Subjective improvement of motor symptoms. Mov Disord. 2004 ; 19: 1102-1106
21. Zanelati TV, Biojone C, Moreira FA, et al. Antidepressant-like effects of cannabidiol in mice: Possible involvement of 5-HT1A receptors. Br J Pharmacol. 2010 ; 159: 122-128
22. Zuardi AW. Cannabidiol: From an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr. 2008 ; 30: 271-280
23. Zuardi AW, Crippa JA, Hallak JE, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol. 2009 ; 23: 979-983
24. Zuardi AW, Morais SL, Guimaraes FS, et al. Antipsychotic effect of cannabidiol. J Clin Psychiatry. 1995 ; 56: 485-486
25. Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl). 1991 ; 104: 260-264